DE69434019D1 - Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung - Google Patents

Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung

Info

Publication number
DE69434019D1
DE69434019D1 DE69434019T DE69434019T DE69434019D1 DE 69434019 D1 DE69434019 D1 DE 69434019D1 DE 69434019 T DE69434019 T DE 69434019T DE 69434019 T DE69434019 T DE 69434019T DE 69434019 D1 DE69434019 D1 DE 69434019D1
Authority
DE
Germany
Prior art keywords
composition
variants
antiviral effect
virus proteins
transdominant variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434019T
Other languages
English (en)
Other versions
DE69434019T2 (de
Inventor
Majid Mehtali
Tania Guss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69434019D1 publication Critical patent/DE69434019D1/de
Publication of DE69434019T2 publication Critical patent/DE69434019T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69434019T 1993-12-13 1994-12-13 Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung Expired - Fee Related DE69434019T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9314914A FR2713651B1 (fr) 1993-12-13 1993-12-13 Nouvelle composition pour un effet antiviral.
FR9314914 1993-12-13
PCT/FR1994/001457 WO1995016780A1 (fr) 1993-12-13 1994-12-13 Composition de variants transdominants de proteines virales pour un effet antiviral

Publications (2)

Publication Number Publication Date
DE69434019D1 true DE69434019D1 (de) 2004-10-28
DE69434019T2 DE69434019T2 (de) 2005-09-15

Family

ID=9453843

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434019T Expired - Fee Related DE69434019T2 (de) 1993-12-13 1994-12-13 Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung

Country Status (8)

Country Link
EP (1) EP0682708B9 (de)
AT (1) ATE277186T1 (de)
AU (1) AU685560B2 (de)
CA (1) CA2155844A1 (de)
DE (1) DE69434019T2 (de)
ES (1) ES2229232T3 (de)
FR (1) FR2713651B1 (de)
WO (1) WO1995016780A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780822B2 (en) 1998-11-02 2005-04-21 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
FR2982277B1 (fr) 2011-11-08 2015-08-21 Agronomique Inst Nat Rech Cassette d'expression inductible et ses utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014427A2 (en) * 1989-05-25 1990-11-29 Sandoz Ltd Multivalent repressor of gene function

Also Published As

Publication number Publication date
DE69434019T2 (de) 2005-09-15
FR2713651A1 (fr) 1995-06-16
ES2229232T3 (es) 2005-04-16
WO1995016780A1 (fr) 1995-06-22
FR2713651B1 (fr) 1996-04-19
AU685560B2 (en) 1998-01-22
EP0682708A1 (de) 1995-11-22
EP0682708B9 (de) 2005-03-02
EP0682708B1 (de) 2004-09-22
CA2155844A1 (fr) 1995-06-22
AU1275095A (en) 1995-07-03
ATE277186T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
EA199901031A1 (ru) Производные бензимидазола
CZ63995A3 (en) Virus vectors and their use in gene therapy
ATE303378T1 (de) Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate- aufnahme
DE69820450D1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
DE69323183D1 (de) Weitere indolderivate mit antiviraler wirkung
CA2051288A1 (en) Viral targeted destruction of neoplastic cells
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
ES2169037T3 (es) Conjugados polietilenglicol-hirudina, su procedimiento de preparacion y su empleo para el tratamiento de las trombosis.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
DE69434019D1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
CA2047802A1 (en) Pharmaceutical compositions
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
EP0739901A3 (de) Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
NO945031L (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
IL99543A0 (en) Oligonucleotides,pharmaceutical compositions containing the same and methods for detection of herpes virus utilizing the same
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee